Thrivent Financial For Lutherans I Teos Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $6,745 - $8,993	616 Added 2.61%	24,223 $265,000
Q2 2023 Aug 14, 2023	SELL	$12.93 - $18.05 $9,296 - $12,977	-719 Reduced 2.96%	23,607 $313,000
Q1 2023 May 17, 2023	SELL	$13.02 - $22.62 $11,106 - $19,294	-853 Reduced 3.39%	24,326 $331,000
Q4 2022 Feb 08, 2023	SELL	$17.77 - $21.6 $3,465 - $4,212	-195 Reduced 0.77%	25,179 $492,000
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $101,760 - $149,084	5,471 Added 27.49%	25,374 $483,000
Q2 2022 Aug 16, 2022	BUY	$16.57 - $35.1 $58,574 - $124,078	3,535 Added 21.6%	19,903 $410,000
Q1 2022 May 13, 2022	BUY	$31.92 - $47.45 $522,466 - $776,661	16,368 New	16,368 $527,000

169

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $285M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.